RE:RE:RE:RE:RE:RE:RE:Interesting Chart Pattern Shows.......Oats and prophet,
Thanks for your replies. I did read again the Noble Capital report and they do have a couple of positive sentences on Gilles' credentials. I realize he has clinical trials experience and worked in big pharma. My point is that Gilles cannot do everthing and the list of diverse project in diverse potential markets with diverse partners is long.
So, while recognizing Gilles does know about pharma, and I am encouraged by that, I feel they need more people taking responsibility for aspects of these processes and ultimately the deals we need to get somewhere.
As far as I can tell, what holds them back is the fear of seeking financing, if the cash flow does not cover more people. That seems to be missing the point that we need people to get to deals. Of course, I have never worked at Ceapro and do not know what if any are the pinch points in making progress. Maybe Gilles can work 18 hours a day and juggle five big projects. Maybe we need insurnace on him if he gets sick. But I do not see a resilient organization if it all depends on the CEO to address management of lots of projects.